rifamycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, rifamycin derivatives | 4817 | 6998-60-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 1.30 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 16, 2018 | FDA | COSMO TECHNOLOGIES |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A07AA13 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | D06AX15 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use |
| ATC | J04AB03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Antibiotics |
| ATC | S01AA16 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
| ATC | S02AA12 | SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives |
| FDA CS | M0019113 | Rifamycins |
| FDA EPC | N0000175500 | Rifamycin Antibacterial |
| MeSH PA | D018501 | Antirheumatic Agents |
| CHEBI has role | CHEBI:33231 | antitubercular agents |
| CHEBI has role | CHEBI:33281 | antibiotics |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Traveler's diarrhea | indication | 11840006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.94 | acidic |
| pKa2 | 7.75 | acidic |
| pKa3 | 8.72 | acidic |
| pKa4 | 11.2 | acidic |
| pKa5 | 12.55 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 194MG BASE | AEMCOLO | REDHILL | N210910 | Nov. 16, 2018 | RX | TABLET, DELAYED RELEASE | ORAL | 8741948 | May 3, 2025 | TREATMENT OF TRAVELERS DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 194MG BASE | AEMCOLO | REDHILL | N210910 | Nov. 16, 2018 | RX | TABLET, DELAYED RELEASE | ORAL | Nov. 16, 2023 | NEW CHEMICAL ENTITY |
| EQ 194MG BASE | AEMCOLO | REDHILL | N210910 | Nov. 16, 2018 | RX | TABLET, DELAYED RELEASE | ORAL | Nov. 16, 2028 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bile salt export pump | Transporter | IC50 | 5.20 | CHEMBL | |||||
| Solute carrier organic anion transporter family member 1B1 | Transporter | INHIBITOR | Ki | 5.70 | IUPHAR | ||||
| Solute carrier organic anion transporter family member 1A2 | Transporter | INHIBITOR | Ki | 4.96 | IUPHAR | ||||
| DNA-directed RNA polymerase subunit beta | Enzyme | INHIBITOR | UNKNOWN | DRUG LABEL | |||||
| Bile salt export pump | Transporter | IC50 | 5.51 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| DU69T8ZZPA | UNII |
| D02549 | KEGG_DRUG |
| 14897-39-3 | SECONDARY_CAS_RN |
| 4038081 | VANDF |
| C0035609 | UMLSCUI |
| CHEBI:26580 | CHEBI |
| RFV | PDB_CHEM_ID |
| CHEMBL437765 | ChEMBL_ID |
| CHEMBL2105680 | ChEMBL_ID |
| 6324616 | PUBCHEM_CID |
| DB11753 | DRUGBANK_ID |
| 2293 | INN_ID |
| C023808 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4570 | IUPHAR_LIGAND_ID |
| 2106357 | RXNORM |
| 299330 | MMSL |
| 33895 | MMSL |
| d08756 | MMSL |
| 006067 | NDDF |
| 006068 | NDDF |
| 406756000 | SNOMEDCT_US |
| 713764001 | SNOMEDCT_US |
| 768973004 | SNOMEDCT_US |
| 768974005 | SNOMEDCT_US |
| 783681005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Aemcolo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57841-1200 | TABLET, DELAYED RELEASE | 194 mg | ORAL | NDA | 30 sections |
| Aemcolo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57841-1200 | TABLET, DELAYED RELEASE | 194 mg | ORAL | NDA | 30 sections |
| Aemcolo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57841-1201 | TABLET, DELAYED RELEASE | 194 mg | ORAL | NDA | 30 sections |
| Aemcolo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57841-1201 | TABLET, DELAYED RELEASE | 194 mg | ORAL | NDA | 30 sections |
| Aemcolo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71068-001 | TABLET, DELAYED RELEASE | 194 mg | ORAL | NDA | 30 sections |